Abstract
LDL apheresis using dextran sulfate cellulose beads has been recognized as the best therapeutics for severe familial hypercholesterolemia. It was approved for commercial distribution by Japanese government in 1986. Since 1986, more than 15,000 treatments have been done on about 600 patients. Most of these patients had coronary disease and whose total cholesterol level could not be kept under 250 mg/dl on drug therapy. Although the therapy does not have long history yet, the beneficial effects of LDL apheresis such as reduction of xanthoma and Achilles tendon thickness, alleviation of angina pectoris and prevention and regression of coronary atherosclerosis have been reported. No serious complication has been reported.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
